Roche's bispecific antibody, Columvi receives European approval for diffuse large B─cell lymphoma after initial therapy
Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not …